AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Avalyn Pharma Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$23.33−0.33 (-1.39%)

Close on Oct 19, 2026

Market cap: $691.75M
P/E (TTM): –
Dividend yield: –

Avalyn Pharma Inc. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Research & Development	25	23	18	15
General & Administrative	6.56	5.02	3.90	3.40
Operating Expenses	31	28	22	19
Operating Income	-31	-28	-22	-19
Interest Expense	0.27	0.10	0	0
Interest & Investment Income	2.50	0.90	1.10	0.70
Other Non-Operating Income	2.36	1.04	1.59	1.21
Income Tax Expense	0	0	0	0
Net Income incl. Noncontrolling Interests	-29	-27	-20	-18
Net Income	-29	-27	-20	-18
Net Income to Common	-29	-27	-20	-18
EPS (Basic)(per share)	-0.98	-21.83	-17.63	-63.24
EPS (Diluted)(per share)	-0.98	-21.83	-17.63	-63.24
Shares Outstanding (Basic, Weighted)(shares)	30	1.23	1.15	0.28
Shares Outstanding (Diluted, Weighted)(shares)	30	1.23	1.15	0.28

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 33.12
Debt to equity: 0.04
Debt to assets: 3.5%
Cash to current liabilities: 2444.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.74
Dividend yield: –